Bizalimogene Ralaplasmid

Summary

Bizalimogene Ralaplasmid (CHEMBL4297247) is a phase-3 clinical-stage gene; indicated across 2 conditions including anus neoplasm and human papilloma virus infection.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Gene
• Indications: 2 conditions
• Clinical trials: 6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297247
Name	Bizalimogene Ralaplasmid
Type	Gene
Max phase	3

Also known as: Bizalimogen ralaplasmido, Bizalimogene ralaplasmid, Bizalimogene ralaplasmide, PGX-3002, VGX-3100, VGX3100, pGX3002, BIZALIMOGENE RALAPLASMID

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
anus neoplasm	2	MONDO:0003046	EFO:0003835
human papilloma virus infection	1	MONDO:0005161	EFO:0001668

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
PHASE3	2
PHASE2	2
PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03185013	PHASE3	COMPLETED	REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)
NCT03721978	PHASE3	COMPLETED	REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)
NCT03180684	PHASE2	COMPLETED	Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)
NCT03499795	PHASE2	COMPLETED	VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2
NCT00685412	PHASE1	COMPLETED	Phase I of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation for CIN 2 or 3
NCT01188850	PHASE1	COMPLETED	Fourth Dose of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + EP in Adult Females Previously Vaccinated With Three Doses of VGX-3100

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).